Shots: The accelerated approval is based on P-II DESTINY-Breast01 study assessing Enhertu (5.4mg/kg) as monothx. in 184 patients with HER2-positive mBC, prior treated with two or more anti-HER2 based regimens […]readmore
Tags : HER-2 Positive